Topic Stock Picks[Evening Edition](1): JAE, Eisai, Daiichi Sankyo | Hot Stocks – Stock Search News

JAE From “Stock Search” multi-function chart

■Japan Aviation Electronics Industry <6807> 2,510 yen+179 Yen (+7.7%) Today’s closing price TSE Prime Top rate of increase
Japan Aviation Electronics Industry <6807> is rapidly growing. After the close of trading on the 24th, in conjunction with the announcement of consolidated financial results for the fiscal year ending March 2024, the company disclosed its earnings forecast for the fiscal year ending March 2025. Sales for this fiscal year are expected to increase by 1.9% from the previous fiscal year to 230 billion yen, and ordinary income is expected to increase by 8.4% to 16 billion yen. Additionally, the year-end dividend for the previous term has been revised up by 5 yen from the previous forecast, and the annual dividend forecast for this term is now 60 yen, an increase of 5 yen. Furthermore, the company announced that it would cancel 22 million shares (23.83% of the total number of issued shares) on May 17th, which attracted a lot of buyers. The exchange rate that is the basis for this fiscal year’s earnings forecast is 1 dollar = 145 yen. In the mobile device market, we expect some products to be affected by customers discontinuing production. On the other hand, demand for automobiles is expected to increase as advanced driver support systems and autonomous driving evolve. In the industrial equipment market, demand related to semiconductor manufacturing equipment is expected to recover in the second half of the year due to the spread of AI. Sales for the fiscal year ending March 2024 were 225,781 million yen, down 4.3% from the previous fiscal year, and ordinary income was 14,762 million yen, down 22.8%.

■Kimura Unity <9368> 1,761 yen+48 Yen (+2.8%) Today’s closing price
Kimura Unity <9368> is solid. At 11:00 a.m. on the 25th, in conjunction with the announcement of the consolidated financial results for the fiscal year ending March 2024, we disclosed our business forecast for the fiscal year ending March 2025, predicting that sales for this fiscal year will be 63 billion yen, an increase of 2.4% from the previous fiscal year, and the final profit will be The forecast is for sales to increase 7.1% year on year to 3.3 billion yen. Continuing from the previous fiscal year, we expect to reach a new record high in profits. Coupled with the annual dividend forecast of 60 yen, an increase of 5 yen from the previous year, the company seems to have been well received. The plan is to secure an increase in profits by expecting a wage increase rate of 6% or more. In the mainstay logistics services business, the company expects to expand its area by promoting area strategies, and in the automobile services business, it also expects to see increases in sales and profits.

■Eisai <4523> 6,259 yen+170 Yen (+2.8%) Today’s closing price
While the overall market is weak, Eisai <4523> is reversing high. The company announced on the 24th that global sales revenue for the dementia treatment drug “Recanemab (product name: Rekenbi)” jointly developed with U.S.-based Biogen was 2.83 billion yen for the January-March period of 2024. It was announced that the increase was approximately 2.7 times compared to the previous quarter, October-December 2023. It appears that there was some buying in anticipation of the positive effect that the strong sales situation would have on profits. Along with Biogen’s financial results announcement, Eisai disclosed preliminary sales and revenue information for lecanemab. Eisai’s financial results for the fiscal year ending March 2024 are scheduled to be announced on May 15th.

■Ogaki Kyoritsu Bank <8361> 2,281 yen+55 Yen (+2.5%) Today’s closing price
Ogaki Kyoritsu Bank <8361> is solid. After the close of trading on the 24th, the company announced that its net income for the fiscal year ending March 2024 appeared to have exceeded its plan by 3.2 billion yen, reaching 9.4 billion yen (up 94.8% from the previous period). This provided support for stock prices. Ordinary profit appears to have exceeded the plan by 4.3 billion yen at 14.4 billion yen (up 53.6% year on year). While profits from loan interest and commission transactions exceeded expectations, expenses are expected to be lower than planned.

■ Natori <2922> 2,128 yen+24 Yen (+1.1%) Today’s closing price
Natori <2922> continues to grow. After the close of trading on the 24th, regarding the consolidated results for the fiscal year ending March 2024, sales were 47.5 billion yen (5.3% increase compared to the previous period), 1.8 billion yen higher than planned, and final profit was 290 million yen higher than planned. The company announced that it appears to have surpassed the yen by 1.4 billion yen (3.4 times higher than the previous year). At the same time, the company revised its year-end dividend forecast by 1 yen to 12 yen, which was received favorably. In addition to the effects of price revisions, measures such as cost control were successful. The annual dividend forecast is 23 yen (an increase of 1 yen).

■Enplus <6961> 8,420 yen+90 Yen (+1.1%) Today’s closing price
Enplus <6961> will make a comeback after the morning break. After the close of trading on the 24th, the consolidated results for the fiscal year ending March 2024 are 37.8 billion yen (down 10.5% from the previous period) by 1.7 billion yen below plan, and final profit is 800 million yen below plan. It was announced that it appears to have landed at 3.4 billion yen (down 26.4% from the previous year). In the semiconductor business, market adjustments for server and mobile applications continued, resulting in a delay in recovery. Sales of optical devices also temporarily decreased due to a shortage of parts related to optical transceivers. In response to this, there was early selling in the morning, but it seems that there was a perception that bad news had run out, and there was some buying on the downside.

■Eiken Chemical <4549> 2,025 yen+20 Yen (+1.0%) Today’s closing price
Eiken Chemical <4549> made a slight rebound. After the close of trading on the 24th, the company announced the cancellation of its treasury stock. It seems that there was some buying as they perceived that the potential risk of deterioration in supply and demand due to the re-release of stocks has receded. 1.5 million shares, equivalent to 3.75% of the total number of outstanding shares as of the end of March, will be canceled on April 26th.

■Daiichi Sankyo <4568> 4,766 yen+37 Yen (+0.8%) Today’s closing price
Daiichi Sankyo <4568> was bought in the latter part of the market, and at one point rose more than 5% from the previous day. At 1:00 p.m. on the 25th, along with the announcement of consolidated financial results for the fiscal year ending March 2024, the company announced that it would acquire a total of 55 million shares (2.87% of the total number of issued shares excluding treasury stock) and buy back its own shares for a total acquisition amount of up to 200 billion yen. The implementation was announced. The company also announced plans to increase the annual dividend for the fiscal year ending March 2025 by 10 yen from the previous year to 60 yen, which appears to have supported the stock price. For the fiscal year ending March 2025, sales revenue is expected to increase by 9.3% from the previous year to 1.75 trillion yen, and final profit is expected to decrease by 5.3% from the previous year to 190 billion yen. Sales of mainstay products such as Enhertz, Lixiana, and Tarige are expected to grow. On the other hand, we expect a decrease in final profit due to a decrease in interest income due to a decrease in US dollar-denominated financial assets, and a rebound from the decrease in tax expenses in the previous fiscal year due to the impact of tax effect accounting related to the decision to transfer Daiichi Sankyo Espha’s shares. . The acquisition period for own shares is from April 26th to January 15th, 2025. The acquired treasury stock will be canceled on January 31, 2025.

■Renesas <6723> 2,534 yen+12.5 Yen (+0.5%) Today’s closing price
Renesas Electronics <6723> continued to rise, temporarily recovering to the 2,600 yen level, surpassing the 75-day moving average, and showing signs of quickly eliminating the negative difference between the price and the 25-day moving average. The company announced its financial results for the January-March period of 2024 on the morning of the 25th, and its operating profit was 77,836 million yen, down 37% from the same period last year. Although the weaker yen provided a tailwind, demand for in-vehicle microcontrollers was weak. However, it appears that institutional investors have encouraged short sellers to buy back stocks through stock lending, which has buoyed the stock price. In the market, “The consensus was for operating profit for the first quarter to be 71 billion yen, and the fact that it was significantly higher than that has panicked short sellers.It also seems to have encouraged follow-on buying due to the reasonable price.” (Medium-sized securities strategist) ) was the view expressed.

■CUC <9158> 1,790 yen-387 Yen (-17.8%) Today’s closing price
CUC <9158> has fallen sharply, hitting a new low since listing. After the close of trading on the 24th, in conjunction with the announcement of consolidated financial results for the fiscal year ending March 2024, the company disclosed its earnings forecast for the fiscal year ending March 2025. Revenue for this fiscal year is expected to be 42.9 billion yen, an increase of 29.9% from the previous fiscal year. Final profit is expected to fall 15.2% year on year to 2.2 billion yen, a decline from the previous fiscal year’s level, which exceeded expectations. The company also predicted that its adjusted final profit, which excludes the impact of foreign exchange gains related to loans to its U.S. subsidiary in the previous fiscal year, would increase 5.6% year on year to 2.2 billion yen, but disappointing sales are likely to increase. Ta. In the home visiting nursing segment, we anticipate a decline in sales of coronavirus-related services and other services, as well as a certain level of cost increase aimed at growing the U.S. business and creating synergies between businesses. Revenue for the fiscal year ending March 2024 was 33,025 million yen, 1,162 million yen more than planned (down 6.2% from the previous period), and final profit was 2,595 million yen, 562 million yen more than planned. (up 7.1% year on year). In addition to the impact of making a clinic operating company in the United States a consolidated subsidiary, there was also a foreign exchange gain related to intra-group loans to a US subsidiary, and results exceeded the plan.

Stock search news